3/31
08:00 am
howl
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
3/12
10:33 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Medium
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
3/12
08:06 am
howl
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Low
Report
Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
3/12
08:05 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
3/11
08:25 am
howl
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/11
07:00 am
howl
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
3/4
08:00 am
howl
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Low
Report
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
2/24
07:30 am
howl
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Medium
Report
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
1/14
09:28 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its price target lowered by analysts at JMP Securities from $12.00 to $4.00. They now have a "market outperform" rating on the stock.
Low
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its price target lowered by analysts at JMP Securities from $12.00 to $4.00. They now have a "market outperform" rating on the stock.
1/13
08:00 am
howl
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
Medium
Report
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook